High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

BACKGROUND: Tuberculosis is the world's leading infectious disease killer. We aimed to identify shorter, safer drug regimens for the treatment of tuberculosis. METHODS: We did a randomised controlled, open-label trial with a multi-arm, multi-stage design. The trial was done in seven sites in So...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Infect Dis
Main Authors: Boeree, Martin J, Heinrich, Norbert, Aarnoutse, Rob, Diacon, Andreas H, Dawson, Rodney, Rehal, Sunita, Kibiki, Gibson S, Churchyard, Gavin, Sanne, Ian, Ntinginya, Nyanda E, Minja, Lilian T, Hunt, Robert D, Charalambous, Salome, Hanekom, Madeleine, Semvua, Hadija H, Mpagama, Stellah G, Manyama, Christina, Mtafya, Bariki, Reither, Klaus, Wallis, Robert S, Venter, Amour, Narunsky, Kim, Mekota, Anka, Henne, Sonja, Colbers, Angela, van Balen, Georgette Plemper, Gillespie, Stephen H, Phillips, Patrick P J, Hoelscher, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier Science ;, The Lancet Pub. Group 2017
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5159618/
https://ncbi.nlm.nih.gov/pubmed/28100438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(16)30274-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados